(71) conducted a clinical study to evaluate the safety, efficacy, and anti-tumor immune response in patients with stage IIIB/IV NSCLC who received intratumoral vaccination with autologous DCs transduced with an adenoviral vector expressing CCL21 gene (Ad-CCL21-DC). The gene discussed is CCL21; the disease is neoplasm.